$1.05
+0.08
(+8.25%)▲
Live
10.47%
Downside
Day's Volatility :10.89%
Upside
0.47%
30.32%
Downside
52 Weeks Volatility :72.18%
Upside
60.08%
Period | Scilex Holding Co | Index (Russel 2000) |
---|---|---|
3 Months | -44.25% | 0.0% |
6 Months | 1.96% | 0.0% |
1 Year | -43.27% | 0.0% |
3 Years | -89.63% | -23.0% |
Market Capitalization | 137.9M |
Book Value | -$1.77 |
Earnings Per Share (EPS) | -1.44 |
Wall Street Target Price | 8.83 |
Profit Margin | -233.88% |
Operating Margin TTM | -95.44% |
Return On Assets TTM | -53.64% |
Return On Equity TTM | 0.0% |
Revenue TTM | 50.8M |
Revenue Per Share TTM | 0.44 |
Quarterly Revenue Growth YOY | 30.099999999999998% |
Gross Profit TTM | 27.2M |
EBITDA | -95.0M |
Diluted Eps TTM | -1.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.85 |
EPS Estimate Next Year | -0.53 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.19 |
What analysts predicted
Upside of 740.95%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 21.0M | - |
Net Income | -178.6M | - |
Net Profit Margin | -849.11% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 23.6M | ↑ 12.01% |
Net Income | -47.5M | ↓ 73.39% |
Net Profit Margin | -201.69% | ↑ 647.42% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 31.3M | ↑ 32.92% |
Net Income | -88.4M | ↑ 86.08% |
Net Profit Margin | -282.35% | ↓ 80.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 38.0M | ↑ 21.45% |
Net Income | -23.4M | ↓ 73.58% |
Net Profit Margin | -61.43% | ↑ 220.92% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 46.7M | ↑ 22.9% |
Net Income | -114.3M | ↑ 389.35% |
Net Profit Margin | -244.59% | ↓ 183.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.6M | ↓ 11.22% |
Net Income | -30.8M | ↑ 71.96% |
Net Profit Margin | -290.62% | ↓ 140.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.6M | ↑ 18.9% |
Net Income | -26.6M | ↓ 13.35% |
Net Profit Margin | -211.8% | ↑ 78.82% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.1M | ↓ 19.59% |
Net Income | -35.5M | ↑ 33.32% |
Net Profit Margin | -351.18% | ↓ 139.38% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.5M | ↑ 33.06% |
Net Income | -21.4M | ↓ 39.77% |
Net Profit Margin | -158.97% | ↑ 192.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↓ 19.15% |
Net Income | -24.4M | ↑ 13.91% |
Net Profit Margin | -223.97% | ↓ 65.0% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 16.4M | ↑ 50.4% |
Net Income | -37.6M | ↑ 54.17% |
Net Profit Margin | -229.58% | ↓ 5.61% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 81.5M | - |
Total Liabilities | 223.2M | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 77.9M | ↓ 4.38% |
Total Liabilities | 301.8M | ↑ 35.23% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 86.5M | ↑ 11.03% |
Total Liabilities | 50.3M | ↓ 83.34% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 101.3M | ↑ 17.08% |
Total Liabilities | 274.2M | ↑ 445.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 86.1M | ↓ 0.55% |
Total Liabilities | 75.0M | ↑ 49.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 126.5M | ↑ 46.96% |
Total Liabilities | 116.0M | ↑ 54.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 80.5M | ↓ 36.32% |
Total Liabilities | 243.2M | ↑ 109.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 101.3M | ↑ 25.81% |
Total Liabilities | 274.2M | ↑ 12.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 91.2M | ↓ 9.94% |
Total Liabilities | 281.0M | ↑ 2.47% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 104.5M | ↑ 14.58% |
Total Liabilities | 319.2M | ↑ 13.6% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -60.4M | - |
Investing Cash Flow | -17.6M | - |
Financing Cash Flow | 15.8M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.5M | ↓ 47.93% |
Investing Cash Flow | -25.0K | ↓ 99.86% |
Financing Cash Flow | -19.2M | ↓ 221.51% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.7M | ↓ 8.89% |
Investing Cash Flow | -139.4M | ↑ 557420.0% |
Financing Cash Flow | 28.2M | ↓ 246.91% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.3M | ↓ 25.84% |
Investing Cash Flow | -2.1M | ↓ 98.52% |
Financing Cash Flow | 21.2M | ↓ 24.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.7M | ↑ 968.14% |
Investing Cash Flow | -8.0K | ↓ 99.98% |
Financing Cash Flow | 10.6M | ↑ 2395.07% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.5M | ↑ 73.98% |
Investing Cash Flow | -8.0K | ↑ 0.0% |
Financing Cash Flow | 43.5M | ↑ 309.62% |
Sell
Neutral
Buy
Scilex Holding Co is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Scilex Holding Co | 23.35% | 1.96% | -43.27% | -89.63% | -89.63% |
Eli Lilly And Company | -0.06% | 25.52% | 59.19% | 280.63% | 750.68% |
Johnson & Johnson | 1.16% | 10.73% | 9.07% | 1.05% | 28.98% |
Merck & Co. Inc. | -5.99% | -14.37% | 5.18% | 33.92% | 28.61% |
Abbvie Inc | -2.56% | 12.49% | 30.49% | 73.65% | 144.32% |
Amgen Inc. | -4.16% | 18.3% | 17.8% | 53.91% | 58.51% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Scilex Holding Co | NA | NA | NA | -0.85 | 0.0 | -0.54 | NA | -1.77 |
Eli Lilly And Company | 112.5 | 112.5 | 0.87 | 13.38 | 0.59 | 0.14 | 0.01 | 15.06 |
Johnson & Johnson | 27.19 | 27.19 | 0.96 | 9.93 | 0.22 | 0.08 | 0.03 | 29.72 |
Merck & Co. Inc. | 20.32 | 20.32 | 0.08 | 7.9 | 0.33 | 0.11 | 0.03 | 17.19 |
Abbvie Inc | 63.07 | 63.07 | 0.45 | 10.87 | 0.54 | 0.08 | 0.03 | 3.84 |
Amgen Inc. | 55.5 | 55.5 | 2.24 | 19.49 | 0.49 | 0.04 | 0.03 | 11.03 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Scilex Holding Co | Buy | $137.9M | -89.63% | NA | -233.88% |
Eli Lilly And Company | Buy | $826.6B | 750.68% | 112.5 | 18.86% |
Johnson & Johnson | Buy | $395.9B | 28.98% | 27.19 | 16.74% |
Merck & Co. Inc. | Buy | $278.2B | 28.61% | 20.32 | 21.99% |
Abbvie Inc | Buy | $333.1B | 144.32% | 63.07 | 9.71% |
Amgen Inc. | Buy | $172.7B | 58.51% | 55.5 | 10.12% |
Insights on Scilex Holding Co
Revenue is up for the last 2 quarters, 10.88M → 16.37M (in $), with an average increase of 33.5% per quarter
Netprofit is down for the last 3 quarters, -21.4M → -37.58M (in $), with an average decrease of 34.0% per quarter
In the last 1 year, Eli Lilly And Company has given 57.0% return, outperforming this stock by 97.9%
Armistice Capital, LLC
State Street Corp
BlackRock Inc
Vanguard Group Inc
Geode Capital Management, LLC
Northern Trust Corp
Organization | Scilex Holding Co |
Employees | 113 |
CEO | Dr. Henry H. Ji Ph.D. |
Industry | Healthcare |